ImmunityBio, Inc. announced that its pivotal randomized BCG-naive non-muscle invasive bladder cancer (NMIBC) trial has demonstrated sufficient statistical power to detect clinically meaningful differences between the Anktiva® plus BCG treatment regimen and BCG alone.

OpenAI is close to completing a fundraising round of up to 30 billions USD at a pre-money valuation of 1.25 trillions USD, with lead investments from United Arab Emirates investors and Coatue. OpenAI plans to finalize the financing by the end of next week and is simultaneously negotiating a business agreement to acquire additional computing power from the UAE. This funding round is positioned as a transitional solution ahead of an IPO. The news of this fundraising comes as U.S. tech stocks fell broadly, with the “Magnificent Seven” index dropping by 2.80%.